It’s Time to Evolve Beyond FMTs and Advance LBPs
The FMT era has been productive, but now it’s time to rally together as an industry to accelerate next-generation LBP drug discovery, development and FDA approval.
Lee Swem
Lee Swem is the Chief Development Officer at Kanvas Biosciences, where he leads the development of microbial LBP products. The company’s clinical development programs are focused on microbiome-based treatments for severe unmet needs in humans.
Lee was previously Chief Scientific Officer at Federation Bio, which he helped launch in January 2019. He successfully led the company through a Seed ($10M) and Series A ($50M) financing prior to the assets being acquired by Kanvas Biosciences. Prior to this position, Lee served as SVP and Chief Scientific Officer, VP of Research, and Director of the Therapeutic Antibody Program at Achaogen. Before Achaogen, Lee was a Scientist in the Department of Infectious Disease at Genentech where he started and led the anti-influenza A program, anti-influenza B program, and began a small molecule anti-bacterial program.
Lee received his Ph.D. from Indiana University. Lee has authored several INDs and over 25 patents and publications.